| UCB, Inc |
50474098079 |
RYSTIGGO 140 MG/ML 2 ML VIAL |
Brand |
FDA |
2023-06-27 |
6050.0000 |
None |
1 |
176 |
1 |
1 |
None |
None |
None |
None |
UCB estimates that the average number of patients in the USA who may be prescribed Rystiggo for calendar year 2023 is approximately 176 and for calendar year 2024 is 563. The foregoing estimates are based on UCB analysis of the estimated number of generalized myasthenia gravis (gMG) patients that are (i) anti-acetylcholine receptor antibody-positive (AChR+) with low to moderate restrictiveness, or (ii) muscle-specific tyrosine kinase antibody seropositive with low restrictiveness. UCB used the following sources for the foregoing analysis: IQVIA Pharmetrics, IQVIA LAAD, Symphony Health data and Komodo Heath data |
None |
| UCB, Inc |
50474078185 |
BIMZELX - 160MG/ML 2AINJ US |
Brand |
FDA |
2023-11-13 |
14400.0000 |
None |
1 |
10481 |
None |
None |
None |
None |
None |
None |
UCB estimates that 184 patients on average may be prescribed Bimzelx for the remainder of 2023 and 10,481 patients on average may be prescribed Bimzelx for calendar year 2024. The foregoing estimates are based on UCB analysis of the estimated number of moderate to severe psoriasis patients to be treated with biologics and/or advanced oral products from data received from various internal and external industry data sources. |
None |
| UCB, Inc |
50474078079 |
BIMZELX 160MG/ML 2 - PFS SAFETY SYRINGE |
Brand |
FDA |
2023-11-13 |
14400.0000 |
None |
1 |
10481 |
None |
None |
None |
None |
None |
None |
UCB estimates that 184 patients on average may be prescribed Bimzelx for the remainder of 2023 and 10,481 patients on average may be prescribed Bimzelx for calendar year 2024. The foregoing estimates are based on UCB analysis of the estimated number of moderate to severe psoriasis patients to be treated with biologics and/or advanced oral products from data received from various internal and external industry data sources. |
None |
| United Therapeutics |
66302030002 |
Orenitram 0.125MG Tab 10 ct. Blister Pack |
Brand |
FDA |
2023-03-01 |
66.2000 |
United Therapeutics considers multiple factors when setting a list price for a medicine, including: benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: Ongoing research-investment costs, Medical- and patient-service costs (which may or may not include patient assistance programs and capital-investment costs associated with manufacturing, storage and supply).
Orenitram is an FDA approved treatment which affects a number of patients in the US annually. United Therapeutic's approach will focus on educating healthcare providers on how to identify and diagnose potential patients to provide relief from symptoms as early as possible - the education will provide information about treatment. |
None |
2180 |
None |
None |
None |
None |
None |
None |
Estimated patients is confidential and proprietary, and not publicly available or within the public domain. |
None |
| United Therapeutics |
66302030202 |
Orenitram 0.25MG Tab 10 ct. Blister Pack |
Brand |
FDA |
2023-03-01 |
132.3800 |
United Therapeutics considers multiple factors when setting a list price for a medicine, including: benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: Ongoing research-investment costs, Medical- and patient-service costs (which may or may not include patient assistance programs and capital-investment costs associated with manufacturing, storage and supply).
Orenitram is an FDA approved treatment which affects a number of patients in the US annually. United Therapeutic's approach will focus on educating healthcare providers on how to identify and diagnose potential patients to provide relief from symptoms as early as possible - the education will provide information about treatment. |
None |
2180 |
None |
None |
None |
None |
None |
None |
Estimated patients is confidential and proprietary, and not publicly available or within the public domain. |
None |
| United Therapeutics |
66302031002 |
Orenitram 1.0MG Tab 10 ct. Blister Pack |
Brand |
FDA |
2023-03-01 |
529.5700 |
United Therapeutics considers multiple factors when setting a list price for a medicine, including: benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: Ongoing research-investment costs, Medical- and patient-service costs (which may or may not include patient assistance programs and capital-investment costs associated with manufacturing, storage and supply).
Orenitram is an FDA approved treatment which affects a number of patients in the US annually. United Therapeutic's approach will focus on educating healthcare providers on how to identify and diagnose potential patients to provide relief from symptoms as early as possible - the education will provide information about treatment. |
None |
2180 |
None |
None |
None |
None |
None |
None |
Estimated patients is confidential and proprietary, and not publicly available or within the public domain. |
None |
| United Therapeutics |
66302032502 |
Orenitram 2.5MG Tab 10 ct. Blister Pack |
Brand |
FDA |
2023-03-01 |
1323.9100 |
United Therapeutics considers multiple factors when setting a list price for a medicine, including: benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: Ongoing research-investment costs, Medical- and patient-service costs (which may or may not include patient assistance programs and capital-investment costs associated with manufacturing, storage and supply).
Orenitram is an FDA approved treatment which affects a number of patients in the US annually. United Therapeutic's approach will focus on educating healthcare providers on how to identify and diagnose potential patients to provide relief from symptoms as early as possible - the education will provide information about treatment. |
None |
2180 |
None |
None |
None |
None |
None |
None |
Estimated patients is confidential and proprietary, and not publicly available or within the public domain. |
None |
| United Therapeutics |
66302035002 |
Orenitram 5MG Tab 10 ct. Blister Pack |
Brand |
FDA |
2023-03-01 |
2647.8300 |
United Therapeutics considers multiple factors when setting a list price for a medicine, including: benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: Ongoing research-investment costs, Medical- and patient-service costs (which may or may not include patient assistance programs and capital-investment costs associated with manufacturing, storage and supply).
Orenitram is an FDA approved treatment which affects a number of patients in the US annually. United Therapeutic's approach will focus on educating healthcare providers on how to identify and diagnose potential patients to provide relief from symptoms as early as possible - the education will provide information about treatment. |
None |
2180 |
None |
None |
None |
None |
None |
None |
Estimated patients is confidential and proprietary, and not publicly available or within the public domain. |
None |
| United Therapeutics |
66302036384 |
Orenitram Titration Kit 7-Blister Card Pack 0.125mg and 0.25mg and 1 mg Month 3 |
Brand |
FDA |
2023-03-01 |
5838.8400 |
United Therapeutics considers multiple factors when setting a list price for a medicine, including: benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: Ongoing research-investment costs, Medical- and patient-service costs (which may or may not include patient assistance programs and capital-investment costs associated with manufacturing, storage and supply).
Orenitram is an FDA approved treatment which affects a number of patients in the US annually. United Therapeutic's approach will focus on educating healthcare providers on how to identify and diagnose potential patients to provide relief from symptoms as early as possible - the education will provide information about treatment. |
None |
2180 |
None |
None |
None |
None |
None |
None |
Estimated patients is confidential and proprietary, and not publicly available or within the public domain. |
None |
| United Therapeutics |
66302036128 |
Orenitram Titration Kit 7-Blister Card Pack 0.125mg and 0.25mg Month 1 |
Brand |
FDA |
2023-03-01 |
1390.2000 |
United Therapeutics considers multiple factors when setting a list price for a medicine, including: benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: Ongoing research-investment costs, Medical- and patient-service costs (which may or may not include patient assistance programs and capital-investment costs associated with manufacturing, storage and supply).
Orenitram is an FDA approved treatment which affects a number of patients in the US annually. United Therapeutic's approach will focus on educating healthcare providers on how to identify and diagnose potential patients to provide relief from symptoms as early as possible - the education will provide information about treatment. |
None |
2180 |
None |
None |
None |
None |
None |
None |
Estimated patients is confidential and proprietary, and not publicly available or within the public domain. |
None |
| United Therapeutics |
66302036256 |
Orenitram Titration Kit 7-Blister Card Pack 0.125mg and 0.25mg Month 2 |
Brand |
FDA |
2023-03-01 |
3614.5200 |
United Therapeutics considers multiple factors when setting a list price for a medicine, including: benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: Ongoing research-investment costs, Medical- and patient-service costs (which may or may not include patient assistance programs and capital-investment costs associated with manufacturing, storage and supply).
Orenitram is an FDA approved treatment which affects a number of patients in the US annually. United Therapeutic's approach will focus on educating healthcare providers on how to identify and diagnose potential patients to provide relief from symptoms as early as possible - the education will provide information about treatment. |
None |
2180 |
None |
None |
None |
None |
None |
None |
Estimated patients is confidential and proprietary, and not publicly available or within the public domain. |
None |
| Upsher-Smith Laboratories, LLC |
00245600111 |
VIGADRONE® Tablets contain the antiepileptic agent vigabatrin in a strength of 500 mg and are indicated for certain patients with infantile spasms and refractory complex partial seizures. |
Generic |
FDA |
2023-07-28 |
14929.0000 |
• The Marketing Plan is to focus on providing patients and providers with a low cost alternative to the brand Sabril, and to provide education about the services Upsher-Smith offers through a specialty pharmacy to help parents and patients manage side effects, provide speed to therapy via rapid shipments, offer bridge supply during insurance interruption, manage transitions from powder dosage form to tablet dosage form & to provide education about the disease state. The marketing activities include a web site, email activities, attending medical conferences, and supporting a small account management team that focuses on centers of excellence. |
None |
11 |
None |
None |
None |
None |
None |
None |
There are ~114 new Vigabatrin patients enrolled in the REMS program each month; 10-15% of those patients are vigabatrin tablet patients |
None |
| USAntibiotics |
81964000354 |
AUGMENTIN ES-600- amoxicillin and clavulanate potassium for suspension |
Brand |
FDA |
2023-04-29 |
915.3600 |
None |
1 |
251100000 |
None |
None |
None |
None |
None |
None |
number of patients represents number of annual patients in US receiving anitibiotic prescriptions |
None |